Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and ...

Cystic neoplasms of the pancreas encompass a heterogeneous group of lesions ranging from benign entities to precursors of invasive carcinoma. Key subtypes include serous cystic neoplasms, mucinous ...

The overall risk of malignancy in pancreatic cysts may be as low as 0.5 to 1.5%, and the annual risk of progression is 0.5%. 7,15 Conversely, studies estimate that 15% of all pancreatic ...

Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a ...

Longer diabetes duration was associated with a significantly increased risk of pancreatic cystic neoplasms. Diabetes was associated with an increased risk of pancreatic cystic neoplasms (PCNs), with ...

Please provide your email address to receive an email when new articles are posted on . AI model demonstrated 94% accuracy in discerning cystic pancreatic focal lesions from solid lesions in ...

A phase Ib study of a pooled synthetic long peptide mutant KRAS vaccine combined with balstilimab/botensilimab in metastatic pancreatic cancer and metastatic MMR ...

Histopathological and immunohistochemical features of the solid pseudopapillary neoplasm. ( A ) Basophilic calcifications within hyalinized fibrous areas (arrows) (H&E, ×400). ( B ) Tumor with focal ...

Characterizing the transformation and diagnosis of atypical lipomatous tumors to dedifferentiated liposarcoma: Single-institutional outcomes. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

REM-422 is the first oral mRNA degrader of MYB demonstrating proof-of-concept in ACC. In this study, pharmacokinetic and pharmacodynamic analyses conirmed robust compound exposure in blood and target ...